Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk factors and outcomes of COVID-19 in adult patients with hematological malignancies: A single-center study showing lower than expected rates of hospitalization and mortality.
Aumann S, Tsubary U, Nachmias B, Ben Yehuda D, Lavie D, Goldschmidt N, Vainstein V, Libster D, Saban R, Shaulov A, Israel S, Avni B, Grisariu S, Bdolah-Amram T, Gatt M, Zimran E. Aumann S, et al. Among authors: vainstein v. Eur J Haematol. 2023 Jul;111(1):135-145. doi: 10.1111/ejh.13977. Epub 2023 Apr 24. Eur J Haematol. 2023. PMID: 37096337
Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?
Vainstein V, Avni B, Grisariu S, Kfir-Erenfeld S, Asherie N, Nachmias B, Auman S, Saban R, Zimran E, Assayag M, Filanovsky K, Horowitz NA, Lebel E, Shaulov A, Gur M, Rosenbluh C, Krichevsky S, Stepensky P, Gatt ME. Vainstein V, et al. Cancers (Basel). 2023 Jul 3;15(13):3471. doi: 10.3390/cancers15133471. Cancers (Basel). 2023. PMID: 37444582 Free PMC article.
Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.
Kugler E, Cohen I, Amitai I, Ram R, Frisch A, Nachmias B, Canaani J, Moshe Y, Krayem B, Aumann S, Henig I, Vainstein V, Shargian L, Ganzel C, Yeshurun M, Levi I, Raanani P, Akria L, Ofran Y, Shimony S, Wolach O. Kugler E, et al. Among authors: vainstein v. Br J Haematol. 2024 May 23. doi: 10.1111/bjh.19548. Online ahead of print. Br J Haematol. 2024. PMID: 38782575
Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma.
Kfir-Erenfeld S, Asherie N, Lebel E, Vainstein V, Assayag M, Dubnikov Sharon T, Grisariu S, Avni B, Elias S, Alexander-Shani R, Bessig N, Shehadeh A, Ishtay A, Zelmanovich V, Zimran E, Pick M, Roziner I, Kenett RS, Cohen YC, Avivi I, Cohen CJ, Gatt MEE, Stepensky P. Kfir-Erenfeld S, et al. Among authors: vainstein v. Blood Adv. 2024 May 20:bloodadvances.2024012967. doi: 10.1182/bloodadvances.2024012967. Online ahead of print. Blood Adv. 2024. PMID: 38768428
Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia.
Nachmias B, Krichevsky S, Filon D, Even-Or E, Gatt ME, Saban R, Avni B, Grisariu S, Aumann S, Vainstein V. Nachmias B, et al. Among authors: vainstein v. Acta Haematol. 2022;145(6):642-649. doi: 10.1159/000526353. Epub 2022 Aug 5. Acta Haematol. 2022. PMID: 35933982 Free PMC article.
44 results